Eli Lilly pulls Cymbalta journal ads following FDA letter

Share this article:
The FDA has called on Eli Lilly to stop running journal ads for Cymbalta as a treatment for nerve pain caused by diabetes because the ads fail to reveal risks of the drug's use.
In a letter posted on the FDA's Web site last week, the agency said that ads are considered Cymbalta promotion even though their main panels don't mention the drug. Cymbalta, also used as an antidepressant, has risks including dementia if used with older antidepressants known as monoamine oxidase inhibitors.
It can also spur allergic reactions, the FDA said. A Lilly spokesperson told the Bloomberg news agency that the ads appeared in the fourth quarter of 2004 and first quarter of 2005 but won't appear again.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.